UCL Trial Reveals Body's Inflammation Off Switch
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UCL researchers found that fat-derived molecules called epoxy-oxylipins calm the immune system by suppressing intermediate monocytes, white blood cells linked to chronic inflammation and tissue damage.
- In a controlled trial, 48 healthy volunteers received a UV-killed E. coli injection to trigger inflammation, then took the drug GSK2256294 — split into prophylactic (two hours before) and therapeutic (four hours after) arms.
- Participants who received the drug saw faster pain resolution and significantly lower intermediate monocyte levels in blood and tissue, though visible symptoms like redness and swelling were not meaningfully changed.
- The team traced the effect to 12,13-EpOME, a specific epoxy-oxylipin that suppresses the p38 MAPK protein signaling pathway driving monocyte transformation — confirmed in lab work and volunteers given a separate p38-blocking drug.
- The study, published in Nature Communications, is the first to map epoxy-oxylipin activity in humans during inflammation and was funded by Arthritis UK, with collaborators from King's College London, Oxford, Queen Mary University of London, and the US National Institute of Environmental Health Sciences.
- Professor Derek Gilroy (UCL) said the drug is already suitable for human use and could be repurposed to treat flares in chronic inflammatory conditions, "an area currently bereft of effective therapies."
- Dr. Caroline Aylott of Arthritis UK called the findings "exciting," noting new pain management options are urgently needed because, as she put it, "everybody's pain is different."
Why it matters: Chronic inflammation drives arthritis, heart disease, and diabetes — conditions affecting millions and lacking safe long-term treatments. The drug tested is already approved for human use, so clinical trials for rheumatoid arthritis and cardiovascular disease could move faster than for an experimental compound. The disconnect between faster pain relief and unchanged visible swelling suggests the therapy targets the immune cells driving chronic tissue damage rather than surface symptoms.
